序号 专利名 申请号 申请日 公开(公告)号 公开(公告)日 发明人
1 羧基芳的催化氢化及其用于纯化粗对苯二甲酸的应用 CN201080043504.1 2010-09-20 CN102574764A 2012-07-11 菲利普·O·努贝尔; 托马斯·M·巴托斯; 萨米尔·塔勒嘉; 斯蒂芬·P·布鲁格
发明提供一种催化剂及其应用和方法,用于将羧基芳选择性氢化成羟烷基芳基一元羧酸。所述催化剂包含铱。
2 含镍和的非晶态合金催化剂、其制备方法及应用 CN97104064.8 1997-04-24 CN1196975A 1998-10-28 马爱增; 陆婉珍; 闵恩泽
一种由0.1~30.0重%Ni-B非晶态合金和金属添加剂M及70.0~99.9重%多孔载体材料组成的负载型催化剂,其Ni与M的原子比为0.1~1000,(Ni+M)与B的原子比为0.5~10.0,比表面10~1000米2/克。该催化剂的制备方法包括在高于溶液凝固点至100℃的范围内将一种Ni与M投料原子比为0.1~80的,含镍和M的多孔载体材料与摩尔浓度0.5~10.0的含NH4-的溶液按0.1~10.0的B与(Ni+M)投料原子比接触。该催化剂具有较高的催化活性。
3 5-溴-2-(α-羟基戊基)苯甲酸钠盐的不同晶型及其制备方法 CN201410313214.4 2014-07-03 CN104086399A 2014-10-08 常俊标; 宋传君
发明公开了不同晶型的5-溴-2-(α-羟基戊基)苯甲酸钠盐及其制备方法,属药物化学领域。所述的5-溴-2-(α-羟基戊基)苯甲酸钠盐不同晶型包括:无定型5-溴-2-(α-羟基戊基)苯甲酸钠盐、5-溴-2-(α-羟基戊基)苯甲酸钠盐晶型A、5-溴-2-(α-羟基戊基)苯甲酸钠盐晶型B。本发明得到的5-溴-2-(α-羟基戊基)苯甲酸钠盐不同晶型在稳定性溶性上均优于混合型5-溴-2-(α-羟基戊基)苯甲酸钠盐,有利于药物应用。同时,5-溴-2-(α-羟基戊基)苯甲酸钠盐不同晶型的治疗效果明显优于5-溴-2-(α-羟基戊基)苯甲酸盐。
4 羟戊基苯甲酸晶体及其制备方法 CN201410056551.X 2014-02-19 CN103992219A 2014-08-20 郑利刚; 杨汉煜; 马玉秀; 杨占坤; 郭明东; 郭晓伟; 李海波; 齐珊
发明公开了羟戊基苯甲酸晶体及其制备方法。本发明羟戊基苯甲酸钾晶体的粉末X-射线衍射在2θ为:7.0±0.2°、20.9±0.2°处有特征峰。本发明羟戊基苯甲酸钾晶体质量稳定,晶型稳定,更适合于贮存和作为原料药使用。
5 一种2-(α-羟基戊基)苯甲酸多晶型及其制备方法、制剂与应用 CN201410118690.0 2014-03-27 CN103896763A 2014-07-02 李彪; 王涌; 杨云
发明公开了一种2-(α-羟基戊基)苯甲酸多晶型及其制备方法、制剂与应用。所述多晶型的粉末X-射线衍射图谱在7.0,20.8和26.4±0.2°的2θ±0.1°反射处显示特征衍射峰。制备方法为选用甲醇、无乙醇、95%乙醇、75%乙醇、50%乙醇和2-丁醇中的一种或任意组合、选用正丙醇和异丙醇中的一种或任意组合或选用正丁醇通过结晶操作方法得到。制剂为所述的多晶型加入药学上可接受的载体和辅料制备成片剂、胶囊剂、颗粒剂、冻干粉针剂和注射液。所述的应用为所述的多晶型在制备治疗神经退行性疾病药物中的应用。本发明2-(α-羟基戊基)苯甲酸钾多晶型性质稳定,适合于工业化生产,为2-(α-羟基戊基)苯甲酸钾药物发展奠定了基础
6 制备三环衍生物的方法 CN201410012470.X 2010-06-29 CN103772193A 2014-05-07 金明华; 芮仁海; 崔钟熙
发明涉及制备三环衍生物的方法,具体涉及以高产率和高纯度制备三环衍生物中间体的方法,该方法包括:将2-氟间苯二甲酸化合物酯化;对该化合物进行取代反应,引入羟基;引入哌啶基;对该化合物进行还原反应,引入羟基;将所得化合物解。本发明还涉及由该中间体制备三环衍生物的方法。不同于用柱色谱纯化物质的传统方法,本发明的方法通过重结晶对物质进行纯化,从而以高生产和高经济可行性以及高产率和高纯度(与传统方法相比)提供三环衍生物及其中间体。此外,不同于使用氢化锂(由于其起火险高而不能在工业上应用)的传统方法,由于本发明的方法使用了起火风险较低的硼氢化钠和氢化锂,所以该方法可被有效地用于工业化大规模生产。
7 新型酚衍生物以及将其作为有效成分的抗锥虫预防治疗 CN200480033945.8 2004-10-18 CN1882523A 2006-12-20 斋本博之; 重政好弘; 北洁; 薮义贞; 细川知良; 山本雅一
发明涉及式(I)所示的化合物及其光学异构体、其药物上可接受的盐,式中,例如,X表示氢原子或卤素原子;R1表示氢原子;R2表示氢原子或原子数1~4的烷基;R3表示-CHO或-COOH;和R4表示-CH=CH-(CH2)p-CH3(式中,p表示1~12的整数)、或者-CH(OH)-(CH2)q-CH3(式中,q表示1~13的整数)、-CH(OH)-CH2-CH(CH3)-(CH2)2-CH=C(CH3)2、-CH=CH-CH(CH3)-(CH2)3-CH(CH3)2、-(CH2)2-CH(CH3)-(CH2)3-CH-(CH3)2、或-(CH2)8-CH3。这些化合物具有抗锥虫活性,因此能够用作为预防治疗锥虫引起的疾病的药剂。
8 制备三环衍生物的方法 CN201410012470.X 2010-06-29 CN103772193B 2015-11-18 金明华; 芮仁海; 崔钟熙
发明涉及制备三环衍生物的方法,具体涉及以高产率和高纯度制备三环衍生物中间体的方法,该方法包括:将2-氟间苯二甲酸化合物酯化;对该化合物进行取代反应,引入羟基;引入哌啶基;对该化合物进行还原反应,引入羟基;将所得化合物解。本发明还涉及由该中间体制备三环衍生物的方法。不同于用柱色谱纯化物质的传统方法,本发明的方法通过重结晶对物质进行纯化,从而以高生产和高经济可行性以及高产率和高纯度(与传统方法相比)提供三环衍生物及其中间体。此外,不同于使用氢化锂(由于其起火险高而不能在工业上应用)的传统方法,由于本发明的方法使用了起火风险较低的硼氢化钠和氢化锂,所以该方法可被有效地用于工业化大规模生产。
9 制备三环衍生物的方法 CN201080037686.1 2010-06-29 CN102548958A 2012-07-04 金明华; 芮仁海; 崔钟熙
发明涉及制备三环衍生物的方法,具体涉及以高产率和高纯度制备三环衍生物中间体的方法,该方法包括:将2-氟间苯二甲酸化合物酯化;对该化合物进行取代反应,引入羟基;引入哌啶基;对该化合物进行还原反应,引入羟基;将所得化合物解。本发明还涉及由该中间体制备三环衍生物的方法。不同于用柱色谱纯化物质的传统方法,本发明的方法通过重结晶对物质进行纯化,从而以高生产和高经济可行性以及高产率和高纯度(与传统方法相比)提供三环衍生物及其中间体。此外,不同于使用氢化锂(由于其起火险高而不能在工业上应用)的传统方法,由于本发明的方法使用了起火风险较低的硼氢化钠和氢化锂,所以该方法可被有效地用于工业化大规模生产。
10 新型酚衍生物以及将其作为有效成分的抗锥虫预防治疗 CN200480033945.8 2004-10-18 CN1882523B 2010-11-17 斋本博之; 重政好弘; 北洁; 薮义贞; 细川知良; 山本雅一
发明涉及式(I)所示的化合物及其光学异构体、其药物上可接受的盐,式中,例如,X表示氢原子或卤素原子;R1表示氢原子;R2表示氢原子或原子数1~4的烷基;R3表示-CHO或-COOH;和R4表示-CH=CH-(CH2)p-CH3(式中,p表示1~12的整数)、或者-CH(OH)-(CH2)q-CH3(式中,q表示1~13的整数)、-CH(OH)-CH2-CH(CH3)-(CH2)2-CH=C(CH3)2、-CH=CH-CH(CH3)-(CH2)3-CH(CH3)2、-(CH2)2-CH(CH3)-(CH2)3-CH-(CH3)2、或-(CH2)8-CH3。这些化合物具有抗锥虫活性,因此能够用作为预防治疗锥虫引起的疾病的药剂。
11 羟基芳香酸的合成方法 CN200780043598.0 2007-11-28 CN101541733A 2009-09-23 J·C·里特
在包含源和与铜配位的配体的反应混合物中,由卤代芳香酸以高收率和高纯度(>95%)制备羟基芳香酸。
12 含镍和的非晶态合金催化剂、其制备方法及应用 CN97104064.8 1997-04-24 CN1089277C 2002-08-21 马爱增; 陆婉珍; 闵恩泽
一种由0.1~30.0重%Ni-B非晶态合金和金属添加剂M及70.0~99.9重%多孔载体材料组成的负载型催化剂,其Ni与M的原子比为0.1~1000,(Ni+M)与B的原子比为0.5~10.0,比表面10~1000米2/克。该催化剂的制备方法包括在高于溶液凝固点至100℃的范围内将一种Ni与M投料原子比为0.1~80的,含镍和M的多孔载体材料与摩尔浓度0.5~10.0的含BH4-的溶液按0.1~10.0的B与(Ni+M)投料原子比接触。该催化剂具有较高的催化活性。
13 METAL COMPOUNDS OF CALIXARENES, DETERGENT COMPOSITIONS CONTAINING THEM AND USE THEREOF IN LUBRICANT COMPOSITIONS US15751506 2016-08-10 US20180237375A1 2018-08-23 Marcello NOTARI; Alberto ROSELLI; Alessandro CASNATI; Francesco SANSONE; Alessandro BURLINI
The present invention relates to a metal compound of calixarene not containing sulfur and dispersible in oil, which can be partially salified, or neutral, or basic or overbased, said calixarene having general formula (I) in which: a) R1, R2, R3 and R4 are independently selected from hydrogen, or a group containing carbon and hydrogen, or a group containing in addition to carbon and hydrogen also heteroatoms, provided that said heteroatoms are not sulfur; b) one of the two substituents R5 and R6 is hydrogen, while the other may be selected from hydrogen, or a linear or branched alkyl with a number of carbon atoms between 1 and 6, preferably methyl, ethyl, 1-propyl, 2-propyl, n-butyl, sec-butyl, more preferably methyl or ethyl; c) n is the number of units of the calixarene ring and is comprised in the range between 4 and 16, preferably between 5 and 12; said calixarene being characterized in that in at least one of the n units of the calixarene ring, at least one of the substituents R1, R2, R3 and R4 contains at least one acid group of carboxylic type available for the reaction with a metal base, with the proviso that said acid group of carboxylic type is not contained in a unit of the calixarene ring derived from salicylic acid.
14 Diels-alder reactions catalyzed by lewis acid containing solids: renewable production of bio-plastics US14561351 2014-12-05 US09108982B2 2015-08-18 Mark E. Davis; Joshua J. Pacheco
The present disclosure is related to silica-based Lewis acid catalysts, being essentially devoid of strong Brønsted acid character, and their ability to effect the [4+2] cycloaddition and dehydrative aromatization of dienes and dienophiles containing oxygenated substituents to form substituted benzene products. In some embodiments, the processes comprise contacting biomass-derived substrates with ethylene to form terephthalic acid and its derivatives.
15 Acid Addition Salt of Donepezil and Pharmaceutical Composition Thereof US14131178 2012-07-03 US20140243278A1 2014-08-28 Sunil Sadanand Nadkarni; Arunkumar Gupta; Jaya Abraham; Manish Parikh; Mahesh Suthar; Bipin Manavadariya; Vivek Mishra
Disclosed is an acid addition salt of donepezil, wherein acid counterion is selected from the group consisting of pamoic acid, cypionic acid, camphor sulfonic acid, enanthic acid, fusidic acid, gluceptic acid, gluconic acid, lactobionic acid, lauric acid, valeric acid, Dibenzoyl-D-Tartaric acid and terephthalic acid. Disclosed is a process for the preparation and pharmaceutical composition comprising the same. More specifically, disclosed is concerned with the pamoate acid addition salts of donepezil. Disclosed also is long acting formulation comprising the acid addition salt of donepezil and process for the preparation thereof.
16 Fluorine-Containing Dicarboxylic Acids and Their Novel Polymer Compounds US13195375 2011-08-01 US20110282026A1 2011-11-17 Satoru NARIZUKA; Yuji Hagiwara; Masashi Nagamori; Kazuhiro Yamanaka
A fluorine-containing dicarboxylic acid represented by formula (1), wherein n represents an integer of 1-4, and the two carboxylic groups are not adjacent to each other on the aromatic ring. It is possible to obtain a linear polymer compound by reacting the fluorine-containing dicarboxylic acid with a comonomer (e.g., diaminodiol). By thermal cyclization, this linear polymer compound can be converted into another polymer compound having superior characteristics.
17 2-(alpha-hydroxypentyl) benzoate and its preparation and use US10512792 2002-05-09 US07550507B2 2009-06-23 Jinghua Yang; Xiaoliang Wang; Zhibin Xu; Ying Peng
The invention relates to new synthetic 2-(α-hydroxypentyl) benzoates, their preparation and pharmaceutical compositions containing such salts as active ingredients. The invention also relates to the use of the compounds for preventing and treating cardioischemia, cerebroischemia and cardiac or cerebral arterial occlusion (obstruction), etc.
18 NOVEL FLUORINE-CONTAINING DICARBOXYLIC ACIDS AND THEIR NOVEL POLYMER COMPOUNDS US12174414 2008-07-16 US20090030173A1 2009-01-29 Satoru Narizuka; Yuji Hagiwara; Masashi Nagamori; Kazuhiro Yamanaka
Disclosed is a fluorine-containing dicarboxylic acid represented by formula (1), wherein n represents an integer of 1-4, and the two carboxylic groups are not adjacent to each other on the aromatic ring. It is possible to obtain a linear polymer compound by reacting the fluorine-containing dicarboxylic acid with a comonomer (e.g., diaminodiol). By thermal cyclization, this linear polymer compound can be converted into another polymer compound having superior characteristics.
19 PROCESS FOR THE SYNTHESIS OF PEPTIDES CONTAINING A 4-HYDROXY-PROLINE SUBSTRUCTURE US11839565 2007-08-16 US20080021225A1 2008-01-24 Bernhard Wietfeld; Walter Prikoszovich; Bernhard Erb; Werner Pachinger
The present invention relates to processes for preparing peptides and to intermediates involved in such processes, e.g. a process for preparing a compound of formula VIII wherein R12 and R13 are as defined herein.
20 Process for the synthesis of peptides containing a 4-hydroxy-proline substructure US10538028 2003-12-11 US07294722B2 2007-11-13 Bernhard Wietfeld; Walter Prikoszovich; Bernhard Erb; Werner Pachinger
The present invention relates to processes for preparing peptides and to intermediates involved in such processes, e.g. a process for preparing a compound of formula VIII wherein R12 and R13 are as defined herein.
QQ群二维码
意见反馈